Paradigm Biopharmaceuticals Partners With UK University for Osteoarthritis Research; Shares Down 4%

MT Newswires Live

04/02

Paradigm Biopharmaceuticals (ASX:PAR) partnered with City St George's, University of London, UK, to assess the effects of pentosan polysulfate sodium on bone marrow lesions in osteoarthritis, according to a Thursday filing with the Australian bourse.

Pentosan polysulfate sodium is the company's investigational therapy under evaluation in phase three clinical development for knee osteoarthritis, the filing said.

The research collaboration is expected to run for about 12 months, per the filing.

Paradigm Biopharmaceuticals shares fell 4% in morning trade on Thursday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2624967523"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2624967523\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2624967523?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 08:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624967523","market":"sh","top_or_hot":-1,"title":"Paradigm Biopharmaceuticals Partners With UK University for Osteoarthritis Research; Shares Down 4%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PBIGF\">Paradigm Biopharmaceuticals</a> (ASX:PAR) partnered with City St George's, University of London, UK, to assess the effects of pentosan polysulfate sodium on bone marrow lesions in osteoarthritis, according to a Thursday filing with the Australian bourse.</p><p>Pentosan polysulfate sodium is the company's investigational therapy under evaluation in phase three clinical development for knee osteoarthritis, the filing said.</p><p>The research collaboration is expected to run for about 12 months, per the filing.</p><p><a href=\"https://laohu8.com/S/PAR.AU\">Paradigm Biopharmaceuticals</a> shares fell 4% in morning trade on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Paradigm Biopharmaceuticals Partners With UK University for Osteoarthritis Research; Shares Down 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nParadigm Biopharmaceuticals Partners With UK University for Osteoarthritis Research; Shares Down 4%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-04-02 08:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PBIGF\">Paradigm Biopharmaceuticals</a> (ASX:PAR) partnered with City St George's, University of London, UK, to assess the effects of pentosan polysulfate sodium on bone marrow lesions in osteoarthritis, according to a Thursday filing with the Australian bourse.</p><p>Pentosan polysulfate sodium is the company's investigational therapy under evaluation in phase three clinical development for knee osteoarthritis, the filing said.</p><p>The research collaboration is expected to run for about 12 months, per the filing.</p><p><a href=\"https://laohu8.com/S/PAR.AU\">Paradigm Biopharmaceuticals</a> shares fell 4% in morning trade on Thursday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PAR.AU","symbol_name":"PARADIGM BIOPHARMACEUTICALS","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2624967523","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624967523","pubTimestamp":1775090076,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Paradigm Biopharmaceuticals  partnered with City St George's, University of London, UK, to assess the effects of pentosan polysulfate sodium on bone marrow lesions in osteoarthritis, according to a Thursday filing with the Australian bourse.Pentosan polysulfate sodium is the company's investigational therapy under evaluation in phase three clinical development for knee osteoarthritis, the filing said.The research collaboration is expected to run for about 12 months, per the filing.Paradigm Biopharmaceuticals shares fell 4% in morning trade on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PAR.AU":"PARADIGM BIOPHARMACEUTICALS","BK7508":"医药生物股","BK7067":"生物科技"},"translate_title":"Paradigm Biopharmaceuticals与英国大学合作开展骨关节炎研究；股价下跌4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAR.AU":1},"content_text":"Paradigm Biopharmaceuticals (ASX:PAR) partnered with City St George's, University of London, UK, to assess the effects of pentosan polysulfate sodium on bone marrow lesions in osteoarthritis, according to a Thursday filing with the Australian bourse.Pentosan polysulfate sodium is the company's investigational therapy under evaluation in phase three clinical development for knee osteoarthritis, the filing said.The research collaboration is expected to run for about 12 months, per the filing.Paradigm Biopharmaceuticals shares fell 4% in morning trade on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}